• 1
    Lloyd-Jones D, Adams R, Carnethon M, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics – 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119(3):480486.
  • 2
    Lakhan SE, Sapko MT. Blood pressure lowering treatment for preventing stroke recurrence: a systematic review and meta-analysis. Int Arch Med. 2009;2(1):30.
  • 3
    Chen G, Hemmelgarn B, Alhaider S, et al. Meta-analysis of adverse cardiovascular outcomes associated with antecedent hypertension after myocardial infarction. Am J Cardiol. 2009;104(1):141147.
  • 4
    Murphy BP, Stanton T, Dunn FG. Hypertension and myocardial ischemia. Med Clin North Am. 2009;93(3):681695.
  • 5
    Franklin SS, Larson MG, Khan SA, et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation. 2001;103:12451249.
  • 6
    Schiele F. Renal dysfunction and coronary disease: a high-risk combination. J Nephrol. 2009;22(1):3945.
  • 7
    Ponnuchamy B, Khalil RA. Cellular mediators of renal vascular dysfunction in hypertension. Am J Physiol Regul Integr Comp Physiol. 2009;296(4):R1001R1018.
  • 8
    Highland KB. Pulmonary arterial hypertension. Am J Med Sci. 2008;335(1):4045.
  • 9
    Wolf HK, Tuomilehto J, Kuulasmaa K, et al. Blood pressure levels in the 41 populations of the WHO MONICA Project. J Hum Hypertens. 1997;11:733742.
  • 10
    Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet. 1997;349:436442.
  • 11
    Bonow RO, Smaha LA, Smith SC Jr, et al. World Heart Day 2002: the international burden of cardiovascular disease: responding to the emerging global epidemic. Circulation. 2002;106:16021605.
  • 12
    Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as firstline agents: a network meta-analysis. JAMA. 2003;289:25342544.
  • 13
    American Heart Association. Heart Disease and Stroke Statistics – 2005 Update. Dallas, Texas: American Heart Association; Dallas, TX: 2005.
  • 14
    Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics—2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007;115:e69e171.
  • 15
    Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA. 2010;303:20432050.
  • 16
    Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics 2009 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119:e1e161.
  • 17
    Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:25602572.
  • 18
    Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension. 2004;43:1017.
  • 19
    Epstein BJ. Improving blood pressure control rates by optimizing combination antihypertensive therapy. Expert Opin Pharmacother. 2010;11:20112026.
  • 20
    Miller L-A, Wade R, Ramaswamy K, et al. Economic evaluation of 4 angiotensin II receptor inhibitors in the treatment of hypertension. CMRO. 2010;26:13071320.
  • 21
    Smith DH. Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension. Drugs. 2008;68(9):12071225.
  • 22
    Hedner T, Oparil S, Rasmussen K, et al. A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension. Am J Hypertens. 1999;12(4 Pt 1):414417.
  • 23
    Kassler-Taub K, Littlejohn T, Elliott W, et al. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan, in mild-to-moderate hypertension. Am J Hypertens. 1998;11(4 Pt 1):445453.
  • 24
    Ball KJ, Williams PA, Stumpe KO. Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives. J Hypertens. 2001;19(Suppl 1):S49S56.
  • 25
    Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens. 2001;3:283291.
  • 26
    Staessen JA, Li Y, Thijs L, Wang JG. Prevention: an update including the 2003–2004 secondary prevention trials. Hypertens Res. 2005;28:385407.
  • 27
    Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomized trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.
  • 28
    Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet. 1995;346:16471653.
  • 29
    Hasford AM, Simons WR. A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J of Human Hypertens. 2002;16:56957.
  • 30
    Borghi C, Dormi A, D’Addato S, et al. Trends in blood pressure control and antihypertensive treatment in clinical practice; the Brisighella Heart Study. J Hypertens. 2004;22:17071716.